Detalles de la búsqueda
1.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
N Engl J Med
; 389(17): 1579-1589, 2023 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37888917
2.
Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
J Allergy Clin Immunol
; 153(4): 1155-1161.e4, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38272373
3.
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy.
Clin Exp Allergy
; 54(4): 241-252, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38332535
4.
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
J Am Acad Dermatol
; 2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38653344
5.
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Acta Derm Venereol
; 104: adv18452, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38708991
6.
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Acta Derm Venereol
; 104: adv19454, 2024 02 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38323500
7.
Biomarkers in atopic dermatitis.
J Allergy Clin Immunol
; 151(5): 1163-1168, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792449
8.
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
Allergy
; 78(8): 2266-2276, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36934403
9.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol
; 189(3): 327-335, 2023 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37177895
10.
A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis.
Br J Clin Pharmacol
; 89(1): 61-79, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36326810
11.
Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis.
Acta Derm Venereol
; 103: adv00881, 2023 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36883875
12.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol
; 103: adv00872, 2023 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36794894
13.
The Treat-to-Target Project in Atopic Dermatitis: One Year On.
Acta Derm Venereol
; 103: adv5382, 2023 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37083095
14.
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
J Eur Acad Dermatol Venereol
; 37(10): 2056-2066, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335885
15.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
J Allergy Clin Immunol
; 149(3): 977-987.e14, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34403658
16.
Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters.
J Allergy Clin Immunol
; 149(1): 125-134, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34237306
17.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 397(10290): 2169-2181, 2021 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34023009
18.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Allergy
; 77(11): 3398-3407, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35837880
19.
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
Br J Dermatol
; 187(6): 888-899, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36082590
20.
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Pediatr Allergy Immunol
; 33(12): e13887, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564878